ATLANTA, March 6, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 33rd Annual Healthcare Conference. The Company''s virtual fireside…

James P Mackin , President & CEO at Artivion (NYSE: AORT ), reported a large insider sell on March 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Mackin sold 22,630 shares of Artivion . The total transaction amounted to $292,786. Artivion shares are trading down 0.69% at $12.95 at the time of this writing on Thursday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. Why Insider Transactions Are Important Insider transactions shouldn''t be used primarily to make … Full story available on Benzinga.com

There''s nothing like an upside earnings surprise to juice the price of a company''s shares.

There''s nothing like an upside earnings surprise to juice the price of a company''s shares.

Artivion press release (AORT): Q4 Non-GAAP EPS of $0.10 beats by $0.12.Revenue of $79.4M (flat Y/Y) misses by $0.77M.Full Year 2022 Financial ResultsTotal revenues for 2022 were…

ATLANTA, Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 financial results will be released on Thursday, February 16, 2023 after the market closes. On…